, a bio/informatics shared resource is still "open for business" - Visit the CDS website


Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 15

Publication Record

Connections

A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.
Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy JP, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly RP, AIDS Clinical Trials Group (ACTG) A5212 Protocol Team
(2014) J Acquir Immune Defic Syndr 66: 399-406
MeSH Terms: Adult, Anti-HIV Agents, CD4 Lymphocyte Count, Dose-Response Relationship, Drug, Double-Blind Method, Female, Fibroblast Growth Factor 7, HIV Infections, HIV-1, Humans, Male, Middle Aged, RNA, Viral, Recombinant Proteins, Thymus Gland, Viral Load
Show Abstract · Added March 13, 2015
BACKGROUND - Poor CD4 lymphocyte recovery on antiretroviral therapy (ART) is associated with reduced function of the thymus. Palifermin (keratinocyte growth factor), by providing support to the thymic epithelium, promotes lymphopoiesis in animal models of bone marrow transplantation and graft-versus-host disease.
METHODS - In AIDS Clinical Trials Group A5212, a randomized, double-blind, placebo-controlled study, 99 HIV-infected patients on ART with plasma HIV-1 RNA levels ≤200 copies per milliliter for ≥6 months and CD4 lymphocyte counts <200 cells per cubic milliliter were randomized 1:1:1:1 to receive once daily intravenous administration of placebo or 20, 40, or 60 μg/kg of palifermin on 3 consecutive days.
RESULTS - The median change in the CD4 T-cell count from baseline to week 12 was not significantly different between the placebo arm [15 (-16, 23) cells/mm] and the 20-μg/kg dose [11 (2, 32) cells/mm], the 40-μg/kg dose [12 (-2, 25) cells/mm], or the 60-μg/kg dose arm [8 (-13, 35) cells/mm] of palifermin. No significant changes were observed in thymus size or in the number of naive T cells or recent thymic emigrants.
CONCLUSIONS - Palifermin in the doses studied was not effective in improving thymic function and did not raise CD4 lymphocyte counts in HIV-infected patients with low CD4 cell counts despite virologically effective ART.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Myofibroblast keratinocyte growth factor reduces tight junctional integrity and increases claudin-2 levels in polarized Caco-2 cells.
Kim TI, Poulin EJ, Blask E, Bukhalid R, Whitehead RH, Franklin JL, Coffey RJ
(2012) Growth Factors 30: 320-32
MeSH Terms: Amphiregulin, Caco-2 Cells, Cell Communication, Cell Line, Tumor, Cell Membrane Permeability, Cell Proliferation, Claudin-2, Culture Media, Conditioned, EGF Family of Proteins, Electric Impedance, ErbB Receptors, Fibroblast Growth Factor 7, Glycoproteins, Humans, Intercellular Signaling Peptides and Proteins, Intestinal Mucosa, Ligands, Myofibroblasts, Tight Junctions
Show Abstract · Added December 5, 2013
The colonic epithelium is composed of a polarized monolayer sheathed by a layer of pericryptal myofibroblasts (PCMFs). We mimicked these cellular compartments in vitro to assess the effects of paracrine-acting PCMF-derived factors on tight junction (TJ) integrity, as measured by transepithelial electrical resistance (TER). Coculture with 18Co PCMFs, or basolateral administration of 18Co conditioned medium, significantly reduced TER of polarized Caco-2 cells. Among candidate paracrine factors, only keratinocyte growth factor (KGF) reduced Caco-2 TER; basolateral KGF treatment led to time- and concentration-dependent increases in claudin-2 levels. We also demonstrate that amphiregulin (AREG), produced largely by Caco-2 cells, increased claudin-2 levels, leading to epidermal growth factor receptor-mediated TER reduction. We propose that colonic epithelial TJ integrity can be modulated by paracrine KGF and autocrine AREG through increased claudin-2 levels. KGF-regulated claudin-2 induction may have implications for inflammatory bowel disease, where both KGF and claudin-2 are upregulated.
2 Communities
2 Members
0 Resources
19 MeSH Terms
Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, Shore TB, Durrant S, Szer J, Chen MG, Lizambri R, Waller EK
(2012) Bone Marrow Transplant 47: 1350-5
MeSH Terms: Acute Disease, Adolescent, Adult, Double-Blind Method, Female, Fibroblast Growth Factor 7, Graft vs Host Disease, Hematologic Neoplasms, Humans, Immunosuppressive Agents, Male, Middle Aged, Stem Cell Transplantation, Stomatitis, Transplantation Conditioning, Transplantation, Homologous
Show Abstract · Added March 5, 2014
This prospective, randomized, double-blind, placebo-controlled study evaluated the efficacy of palifermin to reduce the incidence of severe (grade 3-4) acute GVHD after myeloablation and allo-SCT. Adults who received allo-SCT for hematologic malignancies received placebo or palifermin 60 μg/kg daily on three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning, but often 1 or 2 days before allo-SCT. Subjects received MTX (plus CYA or tacrolimus) on days 1, 3, 6 and 11. Acute GVHD was evaluated once weekly and oral mucositis was evaluated daily. Subjects were randomly assigned to placebo (n=78) or palifermin (n=77). Conditioning included TBI in approximately half of the subjects (48% placebo, 51% palifermin). The primary efficacy end point, subject incidence of grade 3-4 acute GVHD, was similar between treatment groups (17% placebo, 16% palifermin). Grade 3-4 oral mucositis (73% placebo, 81% palifermin) and other secondary efficacy end points were similar between treatment groups. The most commonly reported treatment-related adverse events were skin/s.c. events such as rash, pruritus, and erythema. This exploratory study of acute GVHD after myeloablation and allo-SCT did not provide evidence of a treatment effect with this dosing regimen of palifermin.
0 Communities
1 Members
0 Resources
16 MeSH Terms
First-class delivery: getting growth factors to their destination.
Davidson JM
(2008) J Invest Dermatol 128: 1360-2
MeSH Terms: Animals, Cytological Techniques, Drug Delivery Systems, Extracellular Matrix, Fibroblast Growth Factor 7, Fibroblast Growth Factors, Gene Transfer Techniques, Genetic Techniques, Humans, Intercellular Signaling Peptides and Proteins, Mice, Models, Biological, Protein Transport, Transfection, Wound Healing
Show Abstract · Added December 10, 2013
Growth factor bioavailability in therapeutic applications such as wound healing is limited by extracellular matrix sequestration, proteolysis, and clearance. Local, transient delivery by gene transfer is an attractive concept. Many transfection strategies are available, and adenoviral vectors are in clinical trials. Keratinocyte growth factor-1 (KGF-1), an epithelial-specific member of the fibroblast growth factor (FGF) family, has achieved limited success in protein formulations. Matrix- and cell-based strategies for delivering a KGF-1 virion to target tissue may improve the reproducibility and efficiency of the process, although the advantages of cell-based therapy must be weighed against its added cost and complexity.
0 Communities
1 Members
0 Resources
15 MeSH Terms
Transforming growth factor-beta stimulates epithelial-mesenchymal transformation in the proepicardium.
Olivey HE, Mundell NA, Austin AF, Barnett JV
(2006) Dev Dyn 235: 50-9
MeSH Terms: Animals, Cell Differentiation, Chick Embryo, Epithelium, Fibroblast Growth Factor 1, Fibroblast Growth Factor 7, Genes, Reporter, Membrane Proteins, Mesoderm, Pericardium, Phosphoproteins, Receptors, Transforming Growth Factor beta, Smad6 Protein, Transforming Growth Factor beta, Zonula Occludens-1 Protein
Show Abstract · Added April 7, 2010
The proepicardium (PE) migrates over the heart and forms the epicardium. A subset of these PE-derived cells undergoes epithelial-mesenchymal transformation (EMT) and gives rise to cardiac fibroblasts and components of the coronary vasculature. We report that transforming growth factor-beta (TGFbeta) 1 and TGFbeta2 increase EMT in PE explants as measured by invasion into a collagen gel, loss of cytokeratin expression, and redistribution of ZO1. The type I TGFbeta receptors ALK2 and ALK5 are both expressed in the PE. However, only constitutively active (ca) ALK2 stimulates PE-derived epithelial cell activation, the first step in transformation, whereas caALK5 stimulates neither activation nor transformation in PE explants. Overexpression of Smad6, an inhibitor of ALK2 signaling, inhibits epithelial cell activation, whereas BMP7, a known ligand for ALK2, has no effect. These data demonstrate that TGFbeta stimulates transformation in the PE and suggest that ALK2 partially mediates this effect.
2005 Wiley-Liss, Inc.
0 Communities
2 Members
0 Resources
15 MeSH Terms
KGF alters gene expression in human airway epithelia: potential regulation of the inflammatory response.
Prince LS, Karp PH, Moninger TO, Welsh MJ
(2001) Physiol Genomics 6: 81-9
MeSH Terms: Active Transport, Cell Nucleus, Cell Division, Cells, Cultured, Chlorides, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, DNA-Binding Proteins, Fibroblast Growth Factor 7, Fibroblast Growth Factors, Gene Expression Profiling, Gene Expression Regulation, Humans, Inflammation, Interferons, Ion Transport, Kinetics, RNA, Messenger, Respiratory Mucosa, STAT1 Transcription Factor, Trans-Activators, Transcription, Genetic
Show Abstract · Added June 9, 2010
Keratinocyte growth factor (KGF) regulates several functions in adult and developing lung epithelia; it causes proliferation, stimulates secretion of fluid and electrolytes, enhances repair, and may minimize injury. To gain insight into the molecular processes influenced by KGF, we applied KGF to primary cultures of well-differentiated human airway epithelia and used microarray hybridization to assess the abundance of gene transcripts. Of 7,069 genes tested, KGF changed expression levels of 910. Earlier studies showed that KGF causes epithelial proliferation, and as expected, treatment altered expression of numerous genes involved in cell proliferation. We found that KGF stimulated transepithelial Cl(-) transport, but the number of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) transcripts fell. Although transcripts for ClC-1 and ClC-7 Cl(-) channels increased, KGF failed to augment transepithelial Cl(-) transport in CF epithelia, suggesting that KGF-stimulated Cl(-) transport in differentiated airway epithelia depends on the CFTR Cl(-) channel. Interestingly, KGF decreased transcripts for many interferon (IFN)-induced genes. IFN causes trafficking of Stat dimers to the nucleus, where they activate transcription of IFN-induced genes. We found that KGF prevented the IFN-stimulated trafficking of Stat1 from the cytosol to the nucleus, suggesting a molecular mechanism for KGF-mediated suppression of the IFN-signaling pathway. These results suggest that in addition to stimulating proliferation and repair of damaged airway epithelia, KGF stimulates Cl(-) transport and may dampen the response of epithelial cells to inflammatory mediators.
0 Communities
1 Members
0 Resources
21 MeSH Terms
Pattern of expression of the KGF receptor and its ligands KGF and FGF-10 during postnatal mouse mammary gland development.
Pedchenko VK, Imagawa W
(2000) Mol Reprod Dev 56: 441-7
MeSH Terms: Animals, DNA Primers, Female, Fibroblast Growth Factor 10, Fibroblast Growth Factor 7, Fibroblast Growth Factors, Gene Expression, Growth Substances, Lactation, Ligands, Mammary Glands, Animal, Mice, Mice, Inbred BALB C, Pregnancy, RNA, Messenger, Receptor, Fibroblast Growth Factor, Type 2, Receptors, Fibroblast Growth Factor, Receptors, Growth Factor, Stromal Cells, Weaning
Show Abstract · Added August 27, 2013
The expression of the KGF receptor (KGFR) and its stromal ligands, KGF and FGF-10, was compared during mouse mammary gland development. KGFR expression in mammary parenchyma is maximal in mature virgin mice, declines during pregnancy and lactation, but rises after weaning. The rise in KGFR mRNA in the virgin animal corresponds to parenchymal growth. The fall in KGFR expression in pregnancy is driven by hormone-induced alveolar differentiation since the level of KGFR mRNA is 5-fold higher in isolated ductal cells compared to alveolar cells. KGF and FGF-10 expression patterns differ during ductal development. FGF-10 is also expressed at about a 15-fold higher molar level than KGF. During pregnancy and lactation, expression of KGF and FGF-10 decreases in intact fat pads but is unchanged in parenchyma-free fat pads. Thus, the decrease in KGF and FGF-10 expression observed in intact glands during pregnancy and lactation is not a direct consequence of the changing hormonal milieu but more likely reflects an increase in the ratio of epithelium to stroma. Differences in the level and pattern of expression of mRNA for KGF, FGF-10, and the KGFR during postnatal development of the mouse mammary gland are a result of morphological development, changes in the ratio of stroma to epithelium, and hormonal regulation of cell differentiation. These changes suggest that the biological roles that these growth factors play are regulated by fluctuations in both growth factor and growth factor receptor expression and that KGF and FGF-10 may have different regulatory functions.
0 Communities
1 Members
0 Resources
20 MeSH Terms
Attenuation and loss of hormonal modulation of KGF (FGF-7)/KGF receptor expression and mitogenesis during mammary tumor progression.
Imagawa W, Pedchenko VK, Helber J, Xing C
(2000) J Cell Physiol 184: 222-8
MeSH Terms: Animals, Cell Transformation, Neoplastic, Female, Fibroblast Growth Factor 10, Fibroblast Growth Factor 7, Fibroblast Growth Factors, Growth Substances, Humans, Keratinocytes, Mammary Glands, Animal, Mammary Neoplasms, Experimental, Mice, Mitogens, Pregnancy, Progesterone, RNA, Messenger, Receptor, Fibroblast Growth Factor, Type 2, Receptors, Fibroblast Growth Factor, Receptors, Growth Factor, Tumor Cells, Cultured
Show Abstract · Added August 27, 2013
Keratinocyte growth factor (KGF), alone and in synergism with progesterone (P) and prolactin (PRL), is mitogenic for normal mammary epithelium (ME) in vitro. In addition, P can upregulate ME sensitivity to KGF by slowing KGF receptor (KGFR) mRNA turnover in vitro. These hormonal interactions with KGF in vitro raise the possibility that alterations in these interactions can play a role in hormone-dependent mammary tumor growth and progression. The effect of hormones on KGF mitogenesis and the regulation of KGFR expression was examined in pregnancy-dependent (PDT) and ovarian-independent (OIT) mouse mammary tumors. In serum-free, collagen gel cell culture, dose/response (2-20 ng/ml) and time course studies showed that KGF stimulated the proliferation of PDT (not OIT) cells but synergism with P or PRL was not observed. The level of KGFR mRNA in PDT cells was not significantly different from normal ME but in OIT it was reduced more than 90%. P did not affect KGFR mRNA turnover in cultured PDT cells. However, KGFR mRNA was more stable in PDT cells compared to normal ME; after 6 days culture in basal medium, KGFR mRNA levels declined 40% vs. 85% previously shown for normal ME. Determination of KGF mRNA levels in tissues showed that it was lower in PDT compared to normal mammary gland and not detectable in OIT. These data show that in PDT both KGF-stimulated mitogenesis and the regulation of KGFR expression are independent of hormones. OIT has progressed to independence from any KGF influence. Thus, a subset of hormonally regulated pathways related to epithelial/stromal cell interactions can be lost in hormone-dependent mammary tumors during tumor progression.
Copyright 2000 Wiley-Liss, Inc.
0 Communities
1 Members
0 Resources
20 MeSH Terms
Estrogen treatment in vivo increases keratinocyte growth factor expression in the mammary gland.
Pedchenko VK, Imagawa W
(2000) J Endocrinol 165: 39-49
MeSH Terms: Age Factors, Animals, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Estradiol, Female, Fibroblast Growth Factor 10, Fibroblast Growth Factor 7, Fibroblast Growth Factors, Growth Substances, Mammary Glands, Animal, Mice, Mice, Inbred BALB C, Ovariectomy, RNA, Messenger, Time Factors, Up-Regulation
Show Abstract · Added August 27, 2013
Proliferation and differentiation of mammary epithelia are regulated by the combined action of systemic hormones and locally derived paracrine growth factors. Keratinocyte growth factor (KGF) is a potential candidate stromal factor that may participate in the hormonal control of stromal/epithelial interactions. In this study, we have examined the in vivo effect of 17beta-estradiol (E) treatment on KGF expression in mammary glands of peripubertal (5-week-old) and mature (11-week-old) mice. Mice received subcutaneous injections of hormone after which KGF mRNA levels were assayed by ribonuclease protection analysis of mammary gland RNA. E treatment caused a dose- and time-dependent increase in KGF mRNA levels in intact mice from both age groups. Neither 17alpha-estradiol nor progesterone injection affected KGF mRNA levels. Comparison of the relative expression of KGF in parenchyma-free fat pads and in intact glands demonstrated that the basal and E-dependent KGF mRNA levels did not require the presence of mammary epithelium. ELISA assay of KGF tissue content demonstrated that concomitantly with an up-regulation of mRNA, E treatment also increased KGF protein in mammary glands from peripubertal and mature mice. These data show that E treatment stimulates both KGF mRNA and protein expression in mammary stroma in vivo and raises the possibility that KGF has a role in E-regulated mammary gland development.
0 Communities
1 Members
0 Resources
17 MeSH Terms
Species-specific detection of growth factor gene expression in developing murine prostatic tissue.
Haughney PC, Hayward SW, Dahiya R, Cunha GR
(1998) Biol Reprod 59: 93-9
MeSH Terms: Animals, Epidermal Growth Factor, Epithelium, ErbB Receptors, Fibroblast Growth Factor 10, Fibroblast Growth Factor 7, Fibroblast Growth Factors, Gene Expression, Growth Substances, Male, Mesoderm, Mice, Mice, Inbred BALB C, Mice, Nude, Polymerase Chain Reaction, Prostate, RNA, Messenger, Rats, Rats, Sprague-Dawley, Species Specificity, Transforming Growth Factor alpha, Transforming Growth Factor beta, Urogenital System
Show Abstract · Added December 10, 2013
The aim of the present study was to develop a method by which the expression of paracrine signaling molecules could be localized to either epithelial or stromal cells of developing prostatic tissue. Heterospecific tissue recombinants composed of mouse urogenital epithelium (mouse UGE) plus rat urogenital mesenchyme (rat UGM) and the reciprocal tissue recombinants, rat urogenital epithelium (rat UGE) plus mouse urogenital mesenchyme (mouse UGM), were grafted under the renal capsule in intact, athymic male mouse and rat hosts. After 2 wk of growth, RNA from the grafts was analyzed by species-specific reverse transcription-polymerase chain reaction for the expression of the mRNA for the following molecules: transforming growth factors beta1, beta3, and alpha; epidermal growth factor; epidermal growth factor receptor; and keratinocyte growth factor. The species of expression of these growth factor and receptor gene products within the heterospecific tissue recombinants was identified, allowing determination of the cell layer in which the genes were expressed. Identification of the tissue-specific expression of the growth factor and growth factor receptor profiles of the epithelium and mesenchyme of this in vivo model provides a basis for understanding the autocrine and paracrine mediators of cell-cell interactions in prostatic development.
0 Communities
1 Members
0 Resources
23 MeSH Terms